Surbhi  Sarna net worth and biography

Surbhi Sarna Biography and Net Worth

Director of Penumbra
Surbhi Sarna has served on the Board since July 2019. Ms. Sarna is currently a Visiting Partner at Y Combinator. In 2011, Ms. Sarna founded nVision Medical, a healthcare company developing pioneering technology to enable early detection of ovarian cancer, with the intention of fulfilling an unmet clinical need. She led the company from its inception and through its earliest days of product development, funding and initial clinical trials. In April 2018, nVision Medical was acquired by Boston Scientific, and Ms. Sarna led the efforts to commercialize the technology developed by nVision Medical at Boston Scientific through July 2020. Prior to her founding of nVision, Ms. Sarna held a variety of roles in healthcare, including roles at BioCardia and Abbott Vascular. Ms. Sarna has also served on the Board of Directors of Progenity, Inc. since July 2021. Ms. Sarna received a BA from the University of California, Berkeley.

What is Surbhi Sarna's net worth?

The estimated net worth of Surbhi Sarna is at least $556,629.30 as of January 2nd, 2024. Ms. Sarna owns 2,295 shares of Penumbra stock worth more than $556,629 as of December 21st. This net worth evaluation does not reflect any other assets that Ms. Sarna may own. Learn More about Surbhi Sarna's net worth.

How do I contact Surbhi Sarna?

The corporate mailing address for Ms. Sarna and other Penumbra executives is One Penumbra Place, Alameda CA, 94502. Penumbra can also be reached via phone at (510) 748-3200 and via email at [email protected]. Learn More on Surbhi Sarna's contact information.

Has Surbhi Sarna been buying or selling shares of Penumbra?

Surbhi Sarna has not been actively trading shares of Penumbra during the last ninety days. Most recently, Surbhi Sarna sold 85 shares of the business's stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $247.68, for a transaction totalling $21,052.80. Following the completion of the sale, the director now directly owns 2,295 shares of the company's stock, valued at $568,425.60. Learn More on Surbhi Sarna's trading history.

Who are Penumbra's active insiders?

Penumbra's insider roster includes Arani Bose (Insider), Adam Elsesser (President, Chairman and CEO), Harpreet Grewal (Director), Don Kassing (Director), Bridget O'Rourke (Director), James Pray (Insider), Johanna Roberts (EVP), Surbhi Sarna (Director), and Thomas Wilder (Director). Learn More on Penumbra's active insiders.

Are insiders buying or selling shares of Penumbra?

In the last twelve months, insiders at the sold shares 25 times. They sold a total of 94,723 shares worth more than $20,157,267.08. The most recent insider tranaction occured on December, 2nd when EVP Johanna Roberts sold 600 shares worth more than $146,694.00. Insiders at Penumbra own 5.0% of the company. Learn More about insider trades at Penumbra.

Information on this page was last updated on 12/2/2024.

Surbhi Sarna Insider Trading History at Penumbra

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2024Sell85$247.68$21,052.802,295View SEC Filing Icon  
7/3/2023Sell27$341.45$9,219.152,550View SEC Filing Icon  
7/1/2022Sell27$124.39$3,358.531,980View SEC Filing Icon  
4/1/2022Sell28$221.71$6,207.882,007View SEC Filing Icon  
1/3/2022Sell94$285.34$26,821.96View SEC Filing Icon  
11/1/2021Sell907$278.06$252,200.42View SEC Filing Icon  
See Full Table

Surbhi Sarna Buying and Selling Activity at Penumbra

This chart shows Surbhi Sarna's buying and selling at Penumbra by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Penumbra Company Overview

Penumbra logo
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $242.54
Low: $241.24
High: $245.89

50 Day Range

MA: $232.15
Low: $202.26
High: $253.59

2 Week Range

Now: $242.54
Low: $148.00
High: $277.34

Volume

943,962 shs

Average Volume

378,241 shs

Market Capitalization

$9.31 billion

P/E Ratio

282.02

Dividend Yield

N/A

Beta

0.51